A newly presented study has uncovered troubling molecular changes in the cervix associated with a common parasitic infection, ...

Lt. Gov. Eleni Kounalakis told CalMatters she will address potential conflicts of interest with her extensive property ...

The Institute of Cancer Research, London (ICR), which has dedicated decades of research to this area, lauded the NHS decision ...

NEW YORK – The UK's National Institute for Health and Care Excellence (NICE) on Friday recommended that the National Health Service make AstraZeneca's AKT pathway inhibitor Truqap (capivasertib) with ...

The Streetjournal Magazine is an online investigating media house that specializes on systematic, serious crimes, political ...

A twice-a-day pill for the most common type of advanced breast cancer has been approved on the NHS in what scientists say is ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Despite significant advances in Parkinson's disease (PD) treatment, it remains incurable, with limited therapeutic options.

A twice-a-day pill for the most common type of advanced breast cancer has been approved on the NHS in what scientists say is a “landmark moment”.

Adding afuresertib to paclitaxel did not improve outcomes in patients with platinum-resistant ovarian cancer in a phase 2 trial.

The biomarker analysis found patients with certain mutations in the PI3K/AKT/mTOR pathway and MAPK pathway may be resistant to Truqap.

Forgotten Runiverse will integrate the PIXEL token from farming game Pixels as the makers of the Ronin-based Ethereum titles ...